Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7956 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.1315 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4024 | 0.4348 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0851 | 0.0739 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4357 | 0.4709 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0518 | 0.0242 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3599 | 0.2673 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0851 | 0.0739 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.1315 | 0.1421 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0518 | 0.0559 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9254 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3611 | 0.3902 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0851 | 0.0679 |
Brugia malayi | hypothetical protein | 0.003 | 0.1315 | 0.0059 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.